
Conference Coverage
Latest Content

Phase 3 Data Back Tau PET Agent Florquinitau F 18 for Detecting Neurofibrillary Tangles in Alzheimer Disease

Mixed Results From Phase 3 Data for AR1001 in Alzheimer Disease

Ketamine for Treatment-Resistant Depression: Practical Clinical Considerations

Morning Rounds: News From November 9-16

The Change That Counts: Rethinking Reproductive Depression Across the Lifespan

Shorts










Digital Edition
Continuing Medical Education
All News

HLP003 achieved statistically significant and clinically meaningful results in the primary and key secondary endpoints starting as early as day 2.

The FDA has approved dexmedetomidine (Igalmi) sublingual film for at-home use.

A critical care physician explains why quiet, hypoactive ICU delirium is often missed and why its effects follow patients long after discharge.

Many traumatic brain injuries result in significant communication impairment across a spectrum that can range from limited speaking to apparent disorders of consciousness such as comas.

Review the timeline for Igalmi in at-home treatment of agitation in bipolar disorder and schizophrenia.

Meta-analysis finds bright light therapy boosts remission and response in nonseasonal depression, offering a low-cost add-on to standard care.

Minerva Neurosciences webinar reported that roluperidone monotherapy improved primary negative symptoms and functioning in stable patients with schizophrenia who had a low relapse risk.

Teacher-recorded classroom engagement scores beat GPA at identifying middle schoolers who reported alcohol or cannabis use by eighth grade.

The FDA seems to have shelved the fast-track drug review initiative launched during the Trump administration.

Oveporexton (Orzeyful) is now available in the US by prescription for the treatment of narcolepsy type 1.

Explore the types of scams encountered in psychiatric practice in order to help identify those at risk.

Mixed-feature depression can signal bipolar risk; spot red flags and consider lurasidone or lumateperone before standard antidepressants.

Explore how OCD and schizophrenia overlap, complicating diagnosis and care, and learn spectrum-based strategies and treatment pitfalls for managing schizo-obsessive symptoms.

How estrogen dips during menstruation, pregnancy, postpartum, and menopause can trigger schizophrenia relapse, and what it means for antipsychotic dosing.

Psychiatric Times honors those who served with reflections from a World War I diary and new studies on veteran PTSD and suicide risk.

















































